Evidence map›Paper›PMID 33066614›Full record

ArticleCancers2020

Prognostic Impact of

Antonio Fernandez-Serra, David S Moura, María Dolores Sanchez-Izquierdo, Silvia Calabuig-Fariñas, Maria Lopez-Alvarez, Andrea Martínez-Martínez, Irene Carrasco-Garcia, Marta Ramírez-Calvo, Elena Blanco-Alcaina, Raquel López-Reig and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Antonio Fernandez-SerraLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
David S MouraInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.ORCID 0000-0002-6514-2419
María Dolores Sanchez-IzquierdoInstituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Silvia Calabuig-FariñasMolecular Oncology Laboratory, Fundación Investigación, Hospital General Universitario de Valencia, 46014 Valencia, Spain.ORCID 0000-0001-7749-174X
Maria Lopez-AlvarezInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.
Andrea Martínez-MartínezLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Irene Carrasco-GarciaInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.
Marta Ramírez-CalvoLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Elena Blanco-AlcainaInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.
Raquel López-ReigLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Antonia Obrador-HeviaGroup of Advanced Therapies and Biomarkers in Clinical Oncology, Institut d'Investigació Sanitària de les Illes Balears (IdISBa-IUNICS), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-4630-2077
Regina AlemanyDepartment of Biology, Balearic Islands University, 07122 Palma de Mallorca, Spain.
Antonio GutierrezHematology Department, University Hospital Son Espases, 07120 Mallorca, Spain.
Nadia HindiInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.ORCID 0000-0002-5864-762X
Andres PovedaMedical Oncology Department, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Jose A Lopez-GuerreroLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.ORCID 0000-0002-7369-8388
Javier Martin-BrotoInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain.ORCID 0000-0001-7350-6916
Instituto de Biomedicina de Sevilla · ESFundación Instituto Valenciano de Oncología · ESUniversitat de València · ESHealth Research Institute of the Balearic Islands · ESHospital Universitario Son Espases · ESInstituto de Investigación Sanitaria La Fe · ESUniversitat de les Illes Balears · ES

Funding

Consejería de la Salud - Junta de Andalusia - Proyectos de investigación coordinados 2016 PC-0537-2016-0537Instituto de Salud Carlos III PI15/01254
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin tumor blocks of 14 and 86 patients were used in the discovery and expansion sets, respectively. GeneChip miRNA v3.0 was employed to identify the miRNAs differentially expressed between relapsed and non-relapsed patient samples, which were validated in the expansion set, by qRT-PCR. RT2 Profiler PCR Array was used for the screening of

Indexed as

caspase-3GISTlet-7emiR-550prognostic biomarkers

Identifiers

PMID33066614
PMCPMC7602387
OpenAlexW3093393139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.